Stocks Health care PCRX
NASDAQ · Health carePacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. brought in $746.2M of revenue over the twelve months to June 30, 2026, up 5.7% from a year earlier. Net income was $14.6M, a net margin of 2.0%. Operating cash flow minus capital spending left $136.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $205.9M in cash against $363.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Pacira BioSciences, Inc. does
Pacira BioSciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PCRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $726.4M | $7M | $0.16 | $136.7M |
| 2024 | $701M | -$99.6M | -$2.15 | $178.8M |
| 2023 | $675M | $42M | $0.89 | $139.5M |
| 2022 | $666.8M | $15.9M | $0.34 | $115.2M |
| 2021 | $541.5M | $42M | $0.92 | $79.9M |
| 2020 | $429.6M | $145.5M | $3.33 | $39.2M |
Latest SEC filings
What Pacira BioSciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026
- June 30, 2026
- June 11, 2026
- June 4, 2026Additional proxy material DEFA14A
- June 1, 2026Additional proxy material DEFA14A
- May 28, 2026Form DFAN14A filing DFAN14A
- May 28, 2026Additional proxy material DEFA14A
Questions about PCRX
What does Pacira BioSciences, Inc. do?
Pacira BioSciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PCRX.
Is Pacira BioSciences, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $14.6M on revenue of $746.2M, a net margin of 2.0%.
How much revenue does Pacira BioSciences, Inc. make?
Over the twelve months to June 30, 2026 Pacira BioSciences, Inc. reported revenue of $746.2M. That is 5.7% more than a year earlier.
When did Pacira BioSciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
Similar companies
Follow PCRX
Get an email when Pacira BioSciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PCRX: get an email when it filesWhere the numbers come from
Financial figures are the values Pacira BioSciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.